Latest Breaking News On - Perrigo rx pharmaceuticals - Page 1 : comparemela.com

Share this article Share this article DUBLIN, March 1, 2021 /PRNewswire/  Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Consumer Self-Care Products, announced today that it has reached a definitive agreement to sell its Generic Rx Pharmaceuticals business to Altaris Capital Partners, LLC for total consideration of $1.55 billion, including $1.5 billion in cash, subject to customary adjustments. As part of the consideration, Altaris will also assume more than $50 million in potential R&D milestone payments and contingent purchase obligations with third-party Rx partners. Perrigo CEO and President Murray S. Kessler commented, The sale of our Generic Rx business is the most impactful step in Perrigo s transformation plan. This transaction establishes Perrigo as a pure-play global consumer self-care company with industry leading fundamentals. Perrigo Consumer Self-Care will have a focused portfolio with over $4 billion in revenues focused on the growing tre

United statesCleary gottliebRosen katzGeorge aitken daviesGarikai nyaruwataMurrays kesslerSchiff hardinGeneric rx pharmaceuticalsPerrigo rx pharmaceuticalsExchange commissionCompany formWhile the companyAltaris capital partnersPerrigo companyGoldman sachs coUs internal revenue service